-Verge Report
Artivion Follows Recommendation To Stop PROACT Xa Clinical Trial
Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to